Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores—Reply
Author:
Affiliation:
1. Department of Medicine, University of Chicago, Chicago, Illinois
2. Department of Public Health Sciences, University of Chicago, Chicago, Illinois
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2807730/jamaoncology_howard_2023_lr_230019_1695221923.29865.pdf
Reference6 articles.
1. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database.;Peiffer;JAMA Oncol,2023
2. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.;Harigopal;Am J Pathol,2010
3. Prognostic importance of low c-erbB2 expression in breast tumors.;Koscielny;J Natl Cancer Inst,1998
4. Discordance between immunohistochemistry and Erb-B2 receptor tyrosine kinase 2 mRNA to determine human epidermal growth factor receptor 2 low status for breast cancer.;Xu;J Mol Diagn,2022
5. Examination of low ERBB2 protein expression in breast cancer tissue.;Fernandez;JAMA Oncol,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3